Business
Bio-Rad Laboratories develops and markets life-science research and clinical-diagnostics products.
Bio-Rad's reported profit far exceeded its thin operating margin because changes in the Sartorius investment can move net income independently of the core diagnostics business.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 0.7%OK
- Profitability — The company moved from a net loss of $1.844B to net income of $759.9MOK
- Cash flow — Free cash flow grew 29.4% to $374.6M from $289.6MOK
- Margins — Operating margin contracted 865 bps to 1.83%Watch
- Accounting — Positive cash flow with investment-driven profitNote
- Insiders — 0 purchases and 2 salesNote
Where the revenue comes from
Fiscal 2025, as BIO-RAD LABORATORIES, INC. reports it. History and quarterly detail are in the app.
- Clinical Diagnostics$1.6B
- Life Science$1.0B
Leadership changes
From BIO-RAD LABORATORIES, INC.'s own filings, the day they're filed.
- Rajat Mehta · Directors · departureeff. 2025-07-23
- James J. Barry · President · appointmenteff. 2024-05-01
- Andrew Last · Chief Operating Officer · departureeff. 2024-04-10
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-30
- 8-K · Company announcement2026-04-24
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIO-RAD LABORATORIES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.